EraCal Therapeutics

2020 Science Start-ups

The Swiss biotech startup EraCal Therapeutics Ltd. aims to develop a novel anti-obesity drug Era-107 with demonstrated superior efficacy and tolerability compared to the standard of care in three vertebrate species – zebrafish, mice, and rat. EraCal, a spin-off from Harvard University and the University of Zurich, holds a worldwide exclusive license for the new chemical entity (patent filed Oct. 2018). An ambitious team with world-class advisors drives the development of Era-107, targeting first-in-human studies in H1/2022. Our zebrafish-based phenotypic screening platform is applicable to additional indications. EraCal secured CHF >1M in non-dilutive financing, won multiple awards (e.g. VentureKick, MIT life science angels award, IMD-startup competition, Nature SpinOff Prize finalist), and closed an oversubscribed CHF 6m seed round to finance the pre-clinical development of Era-107 and to broaden its pipeline in 2019.

Content by this speaker